The Tissue Factor Pathway Inhibitor C536T Mutation is not Associated with the Risk of Stroke in Young Adults

• References

• 1 Kleesiek K, Schmidt M, Gotting C, Brinkmann T, Prohaska W. A first mutation in the human tissue factor pathway inhibitor gene encoding (P151L)TFPI (letter). Blood 1998; 92: 3976-7.
• 2 Kleesiek K, Schmidt M, Gotting C, Schwenz B, Lange S, Muller-Berghaus G, Brinkmann T, Prohaska W. The 536C-➔T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis. Thromb Haemost 1999; 82: 1-5.
• 3 Paciaroni K, Rossi E, Bazzan M, Ireland H, De Stefano V. Prevalence of the C536T mutation in the tissue factor pathway inhibitor (TFPI) gene among patients with venous thromboembolic disease. Thromb Haemost (letter) 2001; 85: 938-9.
• 4 Hessner MJ, Luhm RA. The C536T transition in the tissue factor pathway inhibitor (TFPI) gene does not contribute to risk of venous thrombosis among carriers of factor V Leiden. Thromb Haemost (letter) 2000; 84: 724-5.
• 5 Evans GD, Langdown J, Brown K, Baglin TP. The C536T transition in the tissue factor pathway inhibitor gene is not a common cause of venous thromboembolic disease in the UK population. Thromb Haemost (letter) 2000; 83: 511.
• 6 Gonzalez-Conejero R, Lozano ML, Corral J, Martinez C, Vicente V. The TFPI 536C-➔T mutation is not associated with increased risk for venous or arterial thrombosis (letter). Thromb Haemost 2000; 83: 787-8.
• 7 Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976; 54: 541-53.